CKD-MBD Insights and Innovations for 2025 and Beyond: No Bone Left Uncovered

7 Feb 2025 9:45 a.m. 11:15 a.m.
Gulmohar Hall 302
ArvindBagga Chair India
UttaraDas Chair India

Session Description: 
Hear from the experts about the pathophysiology of CKD-MBD from childhood to the elderly and applying this knowledge in everyday clinical practice. Gain a balanced view of mineral bone disease in CKD, by reviewing a European consensus report and the recent KDIGO controversies conference. Get an update on the challenges and opportunities of existing and emerging bone biomarkers for the evaluation of bone disease in CKD.  
Learning Objectives:
Understanding CKD-MBD management to optimise treatment. Interpreting bone biomarkers

Time Session
9:45 a.m.
10:03 a.m.
What Should a Clinician Know About CKD-MBD in 2025?
HanneJoergensen Speaker hsjorgensen@clin.au.dkAarhus UniversityDenmark
10:03 a.m.
10:21 a.m.
CKD-MBD in Children and Young Adults: What's the Difference?
SukanyaGovindan Speaker sukanyagovindan@gmail.comMehta Children's Hospitals and MGM healthcare, Chennai, IndiaIndia
10:21 a.m.
10:39 a.m.
Progress in CKD-driven Vascular Calcification: From Bench to Bedside
MarcVervloet Speaker Marc.Vervloet@radboudumc.nlRadboud University Medical center, The NetherlandsNetherlands
10:39 a.m.
10:57 a.m.
How to Use Serum Biomarkers for Optimal Management of CKD-MBD
SandroMazzaferro Speaker sandro.mazzaferro@uniroma1.itSapienza University of Rome, ItalyItaly
10:57 a.m.
11:15 a.m.
Q&A